Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17385691rdf:typepubmed:Citationlld:pubmed
pubmed-article:17385691lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0205466lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0011306lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0002199lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0035525lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0035020lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0542341lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C0376249lld:lifeskim
pubmed-article:17385691lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:17385691pubmed:issue5lld:pubmed
pubmed-article:17385691pubmed:dateCreated2007-4-2lld:pubmed
pubmed-article:17385691pubmed:abstractTextA combination of pegylated interferon alpha (PEG-IFNalpha) and ribavirin has been used widely. Enhancement of immune response against hepatitis C virus (HCV) is known to be involved in the efficacy of the combination therapy. The aim of the study was to elucidate whether the frequency or function of immunocompetent blood cells is related to the outcome of the therapy. Twenty-five chronic hepatitis C patients with high viral load of HCV genotype 1 who underwent 48 weeks of PEG-IFNalpha2b and ribavirin therapy were examined. During the treatment, frequencies of dendritic cell subsets, helper T cell subsets, and NK cells were phenotypically determined. In some patients, the ability of dendritic cells to stimulate allogeneic CD4(+)T cells was examined at the end and after the therapy. Among the 25 patients, 11 showed a sustained virological response, 11 a transient response, and 3 no response. In comparison with sustained virological responders, non-sustained virological responders showed impaired dendritic cell function at the end and after the treatment. The transient responders showed a decline of plasmacytoid dendritic cell frequency from Weeks 1-12 and impaired dendritic cell function as well. Even in patients who attained negative serum HCV RNA at Week 12, the transient responders showed a significant decrease of plasmacytoid dendritic cell frequency and impaired dendritic cell function. In conclusion, in PEG-IFNalpha and ribavirin combination therapy for chronic hepatitis C patients, the early-phase plasmacytoid dendritic cell frequency and/or end-of-treatment dendritic cell function are related to the virological outcome of the therapy.lld:pubmed
pubmed-article:17385691pubmed:languageenglld:pubmed
pubmed-article:17385691pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:citationSubsetIMlld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17385691pubmed:statusMEDLINElld:pubmed
pubmed-article:17385691pubmed:monthMaylld:pubmed
pubmed-article:17385691pubmed:issn0146-6615lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:KatoMichioMlld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:HayashiNorioNlld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:KasaharaAkino...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:KantoTatsuyaTlld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:KatayamaKazuh...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:InoueMichiyoMlld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:TakeharaTetsu...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:YakushijinTak...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:SakakibaraMit...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:HiramatsuNaok...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:MiyatakeHidek...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:ItoseIchiyoIlld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:MiyazakiMasan...lld:pubmed
pubmed-article:17385691pubmed:authorpubmed-author:OzeTsugikoTlld:pubmed
pubmed-article:17385691pubmed:issnTypePrintlld:pubmed
pubmed-article:17385691pubmed:volume79lld:pubmed
pubmed-article:17385691pubmed:ownerNLMlld:pubmed
pubmed-article:17385691pubmed:authorsCompleteYlld:pubmed
pubmed-article:17385691pubmed:pagination511-21lld:pubmed
pubmed-article:17385691pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:meshHeadingpubmed-meshheading:17385691...lld:pubmed
pubmed-article:17385691pubmed:year2007lld:pubmed
pubmed-article:17385691pubmed:articleTitleInvolvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.lld:pubmed
pubmed-article:17385691pubmed:affiliationDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan.lld:pubmed
pubmed-article:17385691pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17385691pubmed:publicationTypeClinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17385691lld:pubmed